{"count":5,"limit":50,"offset":0,"edits":[{"id":4989,"actor_id":null,"entity_type":"hypothesis","entity_id":"h-var-d33964b962","action":"update","diff_json":{"after":"## Molecular Mechanism and Rationale\n\nThe therapeutic mechanism centers on mechanotransduction-mediated activation of somatostatin-positive interneurons in entorhinal cortex layer II through ultrasound-sensitive ion channels. When low-intensity focused ultrasound (LIFUS) is applied to EC-II SST interneurons, it activates mechanosensitive PIEZO1 channels and TREK-1 potassium channels, leading to membrane depolarization and subsequent calcium influx through voltage-gated calcium channels. This calcium surge triggers vesicular release of somatostatin peptide, which acts on somatostatin receptors (SSTR1-5) on both local excitatory neurons and downstream hippocampal circuits. The released somatostatin modulates synaptic transmission along the perforant path by reducing glutamate release probability and fine-tuning the excitation-inhibition balance, ultimately enhancing gamma oscillation coherence between hippocampal CA1/CA3 regions and prefrontal cortex.\n\n## Preclinical Evidence\n\nTransgenic mouse models of Alzheimer's disease, including 5xFAD and APP/PS1 mice, demonstrate progressive loss of SST-positive interneurons in entorhinal cortex beginning at 3-4 months of age, correlating with hippocampal-prefrontal gamma desynchronization and spatial memory deficits. In vitro patch-clamp studies of EC-II SST interneurons show robust responses to low-intensity ultrasound stimulation, with 40-60% of cells exhibiting increased firing rates and enhanced somatostatin release as measured by calcium imaging and neuropeptide ELISA. Optogenetic activation of EC-II SST interneurons in 5xFAD mice restores hippocampal theta-gamma coupling and rescues contextual fear memory performance, while chemogenetic silencing of these neurons in wild-type animals reproduces AD-like oscillatory deficits. Single-cell RNA sequencing data reveals that surviving SST interneurons in early AD retain expression of mechanosensitive channels PIEZO1 and TREK-1, providing a molecular basis for ultrasound responsiveness.\n\n## Therapeutic Strategy\n\nThe therapeutic approach employs a closed-loop neurofeedback system combining real-time EEG monitoring with precisely targeted transcranial focused ultrasound delivery. High-density EEG arrays continuously monitor gamma coherence (30-80 Hz) between hippocampal and prefrontal regions, with individualized threshold algorithms determining when coherence falls below patient-specific baseline levels. When gamma desynchronization is detected, the system delivers 500-millisecond ultrasound bursts at 0.5 MHz frequency and 0.3-0.7 W/cm² spatial-peak temporal-average intensity, specifically targeting EC-II based on individual MRI-guided stereotactic coordinates. Treatment protocols involve 30-minute sessions three times weekly, with ultrasound parameters automatically adjusted based on real-time oscillatory responses to optimize SST interneuron activation while avoiding thermal tissue damage.\n\n## Biomarkers and Endpoints\n\nPrimary endpoints include restoration of hippocampal-prefrontal gamma coherence measured by high-density EEG, with successful treatment defined as achieving >70% of age-matched control coherence values during cognitive tasks. Secondary biomarkers encompass CSF somatostatin levels, which should increase following treatment sessions, and functional MRI measures of entorhinal-hippocampal connectivity during episodic memory encoding. Patient stratification relies on baseline EEG gamma power analysis, CSF phospho-tau/Aβ42 ratios, and high-resolution MRI assessment of entorhinal cortex thickness to identify individuals with preserved EC-II architecture suitable for SST interneuron targeting.\n\n## Potential Challenges\n\nThe primary technical challenge involves achieving sufficient spatial resolution to selectively target EC-II SST interneurons while avoiding activation of nearby excitatory neurons or other interneuron subtypes, requiring advances in ultrasound beam focusing and real-time MR thermometry guidance. Individual variations in skull thickness, bone density, and cortical anatomy may compromise ultrasound penetration and focal accuracy, necessitating personalized acoustic modeling and potentially limiting treatment efficacy in patients with significant cortical atrophy. Off-target effects could include unwanted activation of adjacent temporal lobe structures or disruption of normal entorhinal-hippocampal processing rhythms if stimulation parameters are not precisely calibrated.\n\n## Connection to Neurodegeneration\n\nSST interneuron dysfunction represents an early and critical pathological feature in Alzheimer's disease progression, occurring before substantial neuronal loss and contributing directly to circuit-level oscillatory dysfunction that underlies memory consolidation deficits. The selective vulnerability of EC-II SST interneurons to tau pathology and amyloid toxicity disrupts the normal gating of perforant path transmission, leading to aberrant hippocampal excitation patterns and loss of theta-gamma coupling essential for episodic memory formation. By restoring SST interneuron function before extensive neurodegeneration occurs, this therapeutic approach targets a potentially reversible early-stage mechanism rather than attempting to compensate for irreversible neuronal loss in advanced disease stages.\n\n## Evidence enrichment addendum: ecii-sst-real-time-gamma-feedback\n\n        ### Mechanistic focus\n        Real-time gamma feedback, EC-II SST activation, and hippocampal-prefrontal synchrony.\n\n\nThe shared evidence base for this EC layer II vulnerability family is now\nstronger than a generic \"entorhinal dysfunction\" claim. Neuropathology and\nsingle-cell evidence both place transentorhinal and entorhinal circuits at the\nfront of the Alzheimer cascade: Braak staging identified early neurofibrillary\nchange in these regions, modern tau-seeding work shows seeding activity can\nbegin in transentorhinal/entorhinal tissue before widespread cortical spread,\nand recent human cell-type profiling reports layer II entorhinal neurons as a\nselectively vulnerable population at the onset of AD neuropathology (PMID:\n39435008; PMID: 39803521). A 2023 review of entorhinal cortex dysfunction in AD\nalso links medial and lateral EC layer 2 output neurons to the perforant and\ntemporoammonic paths that feed dentate gyrus, CA3, and CA1, making EC-II a\nplausible upstream control point rather than a downstream bystander (PMID:\n36513524). In an EC-tau mouse model, tau pathology was sufficient to produce\nexcitatory neuron loss, degraded grid-cell tuning, altered network activity, and\nspatial memory deficits reminiscent of early AD (PMID: 28111080). The\nneuromodulation branch of this task is additionally supported by 40 Hz gamma\nentrainment studies: optogenetic or sensory gamma stimulation altered amyloid\nburden and microglial state in AD models (PMID: 27929004), and early feasibility\nclinical studies show that noninvasive gamma stimulation can entrain human\nneural activity with acceptable short-term tolerability while leaving efficacy\nas an open question (PMID: 34027028; PMID: 30155285).\n\nThe implication for SciDEX scoring is that EC-II hypotheses should be evaluated\non three separable axes: first, whether the proposed target maps to a layer II\ncell type or projection that is actually vulnerable in AD; second, whether the\nintervention can shift the network state without causing hyperexcitability,\nseizure risk, or nonspecific arousal; and third, whether the readout captures\nearly circuit rescue rather than only late global cognition. Strong support\nwould therefore require convergent biomarkers: tau or p-tau217 to confirm\ndisease stage, high-resolution structural or functional imaging of EC and\nhippocampal subfields, EEG/MEG evidence for theta-gamma coupling or gamma power\nchanges, and a behavioral assay sensitive to path integration, mnemonic\nseparation, or spatial remapping. Weak support would be any result that improves\na broad cognitive endpoint without demonstrating EC engagement, because such a\nsignal could come from attention, sleep, mood, or generalized cortical\nactivation rather than the specific layer II mechanism.\n\n\n        ### Hypothesis-specific interpretation\n        This variant should be evaluated as an adaptive control hypothesis. The differentiator is not ultrasound alone but feedback that updates stimulation based on ongoing gamma coherence, preventing under- or over-driving of a fragile EC-hippocampal-prefrontal loop.\n\n        ### Validation path\n        Benchmark against open-loop stimulation using identical exposure, then require improved gamma coherence, preserved sleep/activity metrics, and reduced tau or p-tau217 trajectory in a staged AD model.\n\n        ### Counterevidence and market caveats\n        Closed-loop biomarkers can be confounded by movement, arousal, and electrode montage. The validation design needs artifact rejection and blinded state classifiers before claiming disease modification. A reasonable Exchange price should increase only when\n        EC engagement, cell-type specificity, and disease-stage matching are\n        demonstrated together. The most informative near-term experiment is a\n        staged design that first confirms the circuit target in an ex vivo or\n        animal model, then tests a closed-loop intervention with blinded\n        oscillatory, pathology, and behavioral endpoints. This keeps the claim\n        falsifiable: failure to engage EC-II physiology, failure to alter tau or\n        amyloid-linked pathology, or benefit that disappears under sham-controlled\n        stimulation would all materially weaken the hypothesis.\n","before":"## Molecular Mechanism and Rationale\n\nThe therapeutic mechanism centers on mechanotransduction-mediated activation of somatostatin-positive interneurons in entorhinal cortex layer II through ultrasound-sensitive ion channels. When low-intensity focused ultrasound (LIFUS) is applied to EC-II SST interneurons, it activates mechanosensitive PIEZO1 channels and TREK-1 potassium channels, leading to membrane depolarization and subsequent calcium influx through voltage-gated calcium channels. This calcium surge triggers vesicular release of somatostatin peptide, which acts on somatostatin receptors (SSTR1-5) on both local excitatory neurons and downstream hippocampal circuits. The released somatostatin modulates synaptic transmission along the perforant path by reducing glutamate release probability and fine-tuning the excitation-inhibition balance, ultimately enhancing gamma oscillation coherence between hippocampal CA1/CA3 regions and prefrontal cortex.\n\n## Preclinical Evidence\n\nTransgenic mouse models of Alzheimer's disease, including 5xFAD and APP/PS1 mice, demonstrate progressive loss of SST-positive interneurons in entorhinal cortex beginning at 3-4 months of age, correlating with hippocampal-prefrontal gamma desynchronization and spatial memory deficits. In vitro patch-clamp studies of EC-II SST interneurons show robust responses to low-intensity ultrasound stimulation, with 40-60% of cells exhibiting increased firing rates and enhanced somatostatin release as measured by calcium imaging and neuropeptide ELISA. Optogenetic activation of EC-II SST interneurons in 5xFAD mice restores hippocampal theta-gamma coupling and rescues contextual fear memory performance, while chemogenetic silencing of these neurons in wild-type animals reproduces AD-like oscillatory deficits. Single-cell RNA sequencing data reveals that surviving SST interneurons in early AD retain expression of mechanosensitive channels PIEZO1 and TREK-1, providing a molecular basis for ultrasound responsiveness.\n\n## Therapeutic Strategy\n\nThe therapeutic approach employs a closed-loop neurofeedback system combining real-time EEG monitoring with precisely targeted transcranial focused ultrasound delivery. High-density EEG arrays continuously monitor gamma coherence (30-80 Hz) between hippocampal and prefrontal regions, with individualized threshold algorithms determining when coherence falls below patient-specific baseline levels. When gamma desynchronization is detected, the system delivers 500-millisecond ultrasound bursts at 0.5 MHz frequency and 0.3-0.7 W/cm² spatial-peak temporal-average intensity, specifically targeting EC-II based on individual MRI-guided stereotactic coordinates. Treatment protocols involve 30-minute sessions three times weekly, with ultrasound parameters automatically adjusted based on real-time oscillatory responses to optimize SST interneuron activation while avoiding thermal tissue damage.\n\n## Biomarkers and Endpoints\n\nPrimary endpoints include restoration of hippocampal-prefrontal gamma coherence measured by high-density EEG, with successful treatment defined as achieving >70% of age-matched control coherence values during cognitive tasks. Secondary biomarkers encompass CSF somatostatin levels, which should increase following treatment sessions, and functional MRI measures of entorhinal-hippocampal connectivity during episodic memory encoding. Patient stratification relies on baseline EEG gamma power analysis, CSF phospho-tau/Aβ42 ratios, and high-resolution MRI assessment of entorhinal cortex thickness to identify individuals with preserved EC-II architecture suitable for SST interneuron targeting.\n\n## Potential Challenges\n\nThe primary technical challenge involves achieving sufficient spatial resolution to selectively target EC-II SST interneurons while avoiding activation of nearby excitatory neurons or other interneuron subtypes, requiring advances in ultrasound beam focusing and real-time MR thermometry guidance. Individual variations in skull thickness, bone density, and cortical anatomy may compromise ultrasound penetration and focal accuracy, necessitating personalized acoustic modeling and potentially limiting treatment efficacy in patients with significant cortical atrophy. Off-target effects could include unwanted activation of adjacent temporal lobe structures or disruption of normal entorhinal-hippocampal processing rhythms if stimulation parameters are not precisely calibrated.\n\n## Connection to Neurodegeneration\n\nSST interneuron dysfunction represents an early and critical pathological feature in Alzheimer's disease progression, occurring before substantial neuronal loss and contributing directly to circuit-level oscillatory dysfunction that underlies memory consolidation deficits. The selective vulnerability of EC-II SST interneurons to tau pathology and amyloid toxicity disrupts the normal gating of perforant path transmission, leading to aberrant hippocampal excitation patterns and loss of theta-gamma coupling essential for episodic memory formation. By restoring SST interneuron function before extensive neurodegeneration occurs, this therapeutic approach targets a potentially reversible early-stage mechanism rather than attempting to compensate for irreversible neuronal loss in advanced disease stages."},"change_reason":"enrich EC-II vulnerability hypotheses with evidence addenda","created_at":"2026-04-21T02:54:50.595930+00:00"},{"id":4988,"actor_id":null,"entity_type":"hypothesis","entity_id":"h-var-d33964b962","action":"update","diff_json":{"after":"55b42e9233ac44b3461591b5d1e895a92065f3fd4def982fd3f4a489e3b7537d","before":"fe7aae903d7571ee04339e5c20b4d0abb1a9504c81a697317b3276aa542bb766"},"change_reason":"enrich EC-II vulnerability hypotheses with evidence addenda","created_at":"2026-04-21T02:54:50.595930+00:00"},{"id":4990,"actor_id":null,"entity_type":"hypothesis","entity_id":"h-var-d33964b962","action":"update","diff_json":{"after":0.78,"before":1.0},"change_reason":"enrich EC-II vulnerability hypotheses with evidence addenda","created_at":"2026-04-21T02:54:50.595930+00:00"},{"id":4991,"actor_id":null,"entity_type":"hypothesis","entity_id":"h-var-d33964b962","action":"update","diff_json":{"after":"2026-04-20 19:54:50.595930-07:00","before":"2026-04-12 20:32:58.456814-07:00"},"change_reason":"enrich EC-II vulnerability hypotheses with evidence addenda","created_at":"2026-04-21T02:54:50.595930+00:00"},{"id":4992,"actor_id":null,"entity_type":"hypothesis","entity_id":"h-var-d33964b962","action":"update","diff_json":{"after":"'-0.7':383 '-1':76,301 '-4':182 '-5':108 '-60':220 '-80':344 '/a':510 '0.3':382 '0.5':378 '2':887 '2023':872 '27929004':983 '28111080':952 '3':181 '30':343,408 '30155285':1015 '34027028':1013 '36513524':918 '39435008':868 '39803521':870 '40':219,963 '500':373 '5xfad':164,248 '70':461 'aberr':703 'accept':1000 'accuraci':596 'achiev':460,544 'acoust':599 'act':103 'activ':37,70,240,430,558,619,773,834,942,998,1167 'actual':1050 'ad':24,275,292,865,879,950,980,1053,1249 'ad-lik':274 'adapt':1186 'addendum':754 'addit':960 'adjac':621 'adjust':418 'advanc':568,749 'age':185,464 'age-match':463 'algorithm':354 'alon':1194 'along':124 'also':880 'alter':940,973,1356 'alzheim':160,655,816 'amyloid':691,974,1360 'amyloid-link':1359 'analysi':505 'anatomi':589 'anim':272,1326 'app/ps1':166 'appli':62 'approach':313,730 'architectur':531 'arous':1070,1264 'array':338 'artifact':1272 'assay':1128 'assess':518 'atrophi':611 'attempt':741 'attent':1161 'automat':417 'averag':390 'avoid':432,557 'axe':1033 'balanc':141 'base':397,419,782,1200 'baselin':363,501 'basi':305 'beam':571 'begin':179,836 'behavior':1127,1340 'benchmark':1221 'benefit':1364 'biomark':436,473,1092,1258 'blind':1275,1336 'bone':585 'braak':818 'branch':955 'broad':1147 'burden':975 'burst':376 'bystand':916 'ca1':902 'ca1/ca3':149 'ca3':900 'calcium':85,91,94,234 'calibr':640 'captur':1076 'cascad':817 'caus':1064 'caveat':1254 'cell':222,281,803,848,938,1044,1293 'cell-typ':847,1292 'center':32 'challeng':538,542 'chang':823,1124 'channel':53,73,78,92,297 'chemogenet':263 'circuit':117,669,810,1078,1319 'circuit-level':668 'claim':798,1279,1345 'clamp':201 'classifi':1277 'clinic':987 'close':317,1256,1332 'closed-loop':316,1255,1331 'cognit':470,1085,1148 'coher':146,342,357,448,467,1204,1234 'combin':321 'come':1159 'compens':743 'compromis':591 'confirm':1099,1317 'confound':1261 'connect':492,641 'consolid':676 'contextu':258 'continu':339 'contribut':665 'control':466,910,1187,1370 'converg':1091 'coordin':404 'correl':186 'cortex':45,153,178,521,876 'cortic':588,610,842,1166 'could':616,1158 'counterevid':1251 'coupl':255,713,1120 'critic':651 'csf':475,506 'damag':435 'data':284 'deficit':196,278,677,946 'defin':458 'degrad':935 'deliv':372 'deliveri':333 'demonstr':168,1151,1302 'densiti':336,453,586 'dentat':898 'depolar':82 'design':1270,1314 'desynchron':192,367 'detect':369 'determin':355 'differenti':1190 'direct':666 'disappear':1366 'diseas':162,657,750,1100,1280,1298 'disease-stag':1297 'disrupt':626,693 'downstream':115,915 'drive':1210 'dysfunct':646,672,797,877 'earli':23,291,649,736,821,949,985,1077 'early-stag':735 'ec':12,65,205,243,395,529,552,683,770,785,885,905,922,1024,1110,1152,1215,1290,1351 'ec-hippocampal-prefront':1214 'ec-ii':11,64,204,242,394,528,551,682,769,904,1023,1350 'ec-tau':921 'ecii':756 'ecii-sst-real-time-gamma-feedback':755 'eeg':325,337,454,502 'eeg/meg':1114 'effect':615 'efficaci':605,1007 'electrod':1266 'elisa':238 'employ':314 'encod':496 'encompass':474 'endpoint':438,440,1149,1341 'engag':1153,1291,1349 'enhanc':143,228 'enrich':753 'entorhin':44,177,490,520,630,796,809,854,875,1380 'entorhinal-hippocamp':489,629 'entorhinal-hippocampal-prefront':1379 'entrain':966,995 'episod':494,716 'essenti':714 'evalu':1029,1183 'evid':155,752,781,804,1115 'ex':1323 'exchang':1284 'excit':139,705 'excitation-inhibit':138 'excitatori':112,561,932 'exhibit':223 'experi':1310 'exposur':1229 'express':294 'extens':725 'failur':1347,1354 'fall':358 'falsifi':1346 'famili':789 'fear':259 'feasibl':986 'featur':653 'feed':897 'feedback':761,768,1196 'fine':135 'fine-tun':134 'fire':225 'first':1034,1316 'focal':595 'focus':8,58,331,572,763 'follow':481 'format':718 'fragil':1213 'frequenc':380 'front':813 'function':485,723,1107 'gamma':5,144,191,254,341,366,447,503,712,760,767,965,971,992,1119,1122,1203,1233,1383 'gamma-guid':4 'gate':90,696 'general':1165 'generic':795 'global':1084 'glutam':130 'grid':937 'grid-cel':936 'guid':6,402 'guidanc':579 'gyrus':899 'high':335,452,515,1103 'high-dens':334,451 'high-resolut':514,1102 'hippocamp':19,116,148,189,251,347,445,491,631,704,776,1112,1216,1381 'hippocampal-prefront':18,188,444,775 'human':846,996 'hyperexcit':1065 'hypothes':1026 'hypothesi':1176,1188,1377 'hypothesis-specif':1175 'hz':345,964 'ident':1228 'identifi':524,820 'ii':13,47,66,206,244,396,530,553,684,771,787,853,906,1025,1043,1173,1352 'imag':235,1108 'implic':1017 'improv':1145,1232 'includ':163,441,617 'increas':224,480,1287 'individu':352,399,525,580 'influx':86 'inform':1306 'inhibit':140 'integr':1132 'intens':57,215,391 'interneuron':15,42,68,175,208,246,289,429,535,555,565,645,686,722 'interpret':1178 'intervent':1057,1334 'involv':407,543 'ion':52 'irrevers':745 'keep':1343 'late':1083 'later':884 'layer':46,786,852,886,1042,1172 'lead':79,701 'leav':1006 'level':364,477,670 'lifus':60 'like':276 'limit':603 'link':881,1361 'lobe':623 'local':111 'loop':318,1218,1225,1257,1333 'loss':170,663,708,747,934 'low':56,214 'low-intens':55,213 'make':903 'map':1039 'market':1253 'match':465,1300 'materi':1374 'may':590 'measur':232,449,487 'mechan':26,31,738,1174 'mechanist':762 'mechanosensit':71,296 'mechanotransduct':35 'mechanotransduction-medi':34 'medial':882 'mediat':36 'membran':81 'memori':195,260,495,675,717,945 'metric':1237 'mhz':379 'mice':167,249 'microgli':977 'millisecond':374 'minut':409 'mnemon':1133 'model':158,600,925,981,1250,1327 'modern':827 'modif':1281 'modul':121 'molecular':25,304 'monitor':326,340 'montag':1267 'month':183 'mood':1163 'mous':157,924 'movement':1263 'mr':577 'mri':401,486,517 'mri-guid':400 'near':1308 'near-term':1307 'nearbi':560 'necessit':597 'need':1271 'network':941,1061 'neural':997 'neurodegener':643,726 'neurofeedback':319 'neurofibrillari':822 'neuromodul':954 'neuron':113,267,562,662,746,855,889,933 'neuropatholog':799,866 'neuropeptid':237 'noninvas':991 'nonspecif':1069 'normal':628,695 'occur':659,727 'off-target':612 'ongo':1202 'onset':863 'open':1010,1224 'open-loop':1223 'optim':427 'optogenet':239,968 'oscil':145 'oscillatori':277,424,671,1337 'output':888 'over-driv':1208 'p':1096,1243 'p-tau217':1095,1242 'paramet':416,636 'patch':200 'patch-clamp':199 'path':127,699,895,1131,1220 'patholog':652,689,927,1338,1362 'patient':361,497,607 'patient-specif':360 'pattern':706 'peak':387 'penetr':593 'peptid':101 'perfor':126,698,892 'perform':261 'person':598 'phospho':508 'phospho-tau':507 'physiolog':1353 'piezo1':72,298 'place':806 'plausibl':908 'pmid':867,869,917,951,982,1012,1014 'point':911 'popul':860 'posit':41,174 'potassium':77 'potenti':537,602,733 'power':504,1123 'precis':328,639 'preclin':154 'prefront':20,152,190,349,446,777,1217,1382 'preserv':527,1235 'prevent':1205 'price':1285 'primari':439,540 'probabl':132 'process':632 'produc':931 'profil':850 'progress':169,658 'project':1047 'propos':1037 'protocol':406 'provid':302 'question':1011 'rate':226 'rather':739,912,1080,1168 'ratio':512 'rational':28 'readout':1075 'real':2,323,422,575,758,765 'real-tim':1,322,421,574,764 'reason':1283 'recent':845 'receptor':106 'reduc':129,1239 'region':150,350,826 'reject':1273 'releas':98,119,131,230 'reli':499 'remap':1137 'reminisc':947 'report':851 'repres':647 'reproduc':273 'requir':567,1090,1231 'rescu':257,1079 'resolut':516,547,1104 'respons':211,308,425 'restor':17,250,442,720 'result':1143 'retain':293 'reveal':285 'revers':734 'review':873 'rhythm':633 'risk':1067 'rna':282 'robust':210 'scidex':1019 'score':1020 'second':1054 'secondari':472 'seed':830,833 'seizur':1066 'select':549,679,858 'sensit':51,1129 'sensori':970 'separ':1032,1134 'sequenc':283 'session':410,483 'sham':1369 'sham-control':1368 'share':780 'shift':1059 'short':1002 'short-term':1001 'show':209,832,989 'signal':1157 'signific':609 'silenc':264 'singl':280,802 'single-cel':279,801 'skull':583 'sleep':1162 'sleep/activity':1236 'somatostatin':40,100,105,120,229,476 'somatostatin-posit':39 'spatial':194,386,546,944,1136 'spatial-peak':385 'specif':362,392,1171,1177,1295 'spread':843 'sst':14,67,173,207,245,288,428,534,554,644,685,721,757,772,1378 'sst-posit':172 'sstr1':107 'stage':737,751,819,1101,1248,1299,1313 'state':978,1062,1276 'stereotact':403 'stimul':217,635,972,993,1199,1226,1371 'strategi':310 'stratif':498 'strong':1086 'stronger':792 'structur':624,1105 'studi':202,967,988 'subfield':1113 'subsequ':84 'substanti':661 'subtyp':566 'success':456 'suffici':545,929 'suitabl':532 'support':961,1087,1139 'surg':95 'surviv':287 'synapt':122 'synchron':1384 'synchroni':21,778 'system':320,371 'target':10,329,393,536,550,614,731,1038,1320 'task':471,958 'tau':509,688,829,923,926,1093,1240,1357 'tau-seed':828 'tau217':1097,1244 'technic':541 'tempor':389,622 'temporal-averag':388 'temporoammon':894 'term':1003,1309 'test':1329 'therapeut':30,309,312,729 'therefor':1089 'thermal':433 'thermometri':578 'theta':253,711,1118 'theta-gamma':252,710,1117 'thick':522,584 'third':1072 'three':411,1031 'threshold':353 'time':3,324,412,423,576,759,766 'tissu':434,839 'togeth':1303 'toler':1004 'toxic':692 'trajectori':1245 'transcrani':7,330 'transentorhin':807 'transentorhinal/entorhinal':838 'transgen':156 'transmiss':123,700 'treatment':405,457,482,604 'trek':75,300 'trigger':96 'tune':136,939 'type':271,849,1045,1294 'ultim':142 'ultrasound':9,50,59,216,307,332,375,415,570,592,1193 'ultrasound-sensit':49 'under':674 'unwant':618 'updat':1198 'upstream':909 'use':1227 'valid':1219,1269 'valu':468 'variant':1180 'variat':581 'vesicular':97 'vitro':198 'vivo':1324 'voltag':89 'voltage-g':88 'vulner':680,788,859,1051 'w/cm':384 'weak':1138 'weaken':1375 'week':413 'whether':1035,1055,1073 'widespread':841 'wild':270 'wild-typ':269 'without':1063,1150 'work':831 'would':1088,1140,1372 'β42':511","before":"'-0.7':383 '-1':76,301 '-4':182 '-5':108 '-60':220 '-80':344 '/a':510 '0.3':382 '0.5':378 '3':181 '30':343,408 '40':219 '500':373 '5xfad':164,248 '70':461 'aberr':703 'accuraci':596 'achiev':460,544 'acoust':599 'act':103 'activ':37,70,240,430,558,619 'ad':24,275,292 'ad-lik':274 'adjac':621 'adjust':418 'advanc':568,749 'age':185,464 'age-match':463 'algorithm':354 'along':124 'alzheim':160,655 'amyloid':691 'analysi':505 'anatomi':589 'anim':272 'app/ps1':166 'appli':62 'approach':313,730 'architectur':531 'array':338 'assess':518 'atrophi':611 'attempt':741 'automat':417 'averag':390 'avoid':432,557 'balanc':141 'base':397,419 'baselin':363,501 'basi':305 'beam':571 'begin':179 'biomark':436,473 'bone':585 'burst':376 'ca1/ca3':149 'calcium':85,91,94,234 'calibr':640 'cell':222,281 'center':32 'challeng':538,542 'channel':53,73,78,92,297 'chemogenet':263 'circuit':117,669 'circuit-level':668 'clamp':201 'close':317 'closed-loop':316 'cognit':470 'coher':146,342,357,448,467 'combin':321 'compens':743 'compromis':591 'connect':492,641 'consolid':676 'contextu':258 'continu':339 'contribut':665 'control':466 'coordin':404 'correl':186 'cortex':45,153,178,521 'cortic':588,610 'could':616 'coupl':255,713 'critic':651 'csf':475,506 'damag':435 'data':284 'deficit':196,278,677 'defin':458 'deliv':372 'deliveri':333 'demonstr':168 'densiti':336,453,586 'depolar':82 'desynchron':192,367 'detect':369 'determin':355 'direct':666 'diseas':162,657,750 'disrupt':626,693 'downstream':115 'dysfunct':646,672 'earli':23,291,649,736 'early-stag':735 'ec':12,65,205,243,395,529,552,683 'ec-ii':11,64,204,242,394,528,551,682 'eeg':325,337,454,502 'effect':615 'efficaci':605 'elisa':238 'employ':314 'encod':496 'encompass':474 'endpoint':438,440 'enhanc':143,228 'entorhin':44,177,490,520,630,754 'entorhinal-hippocamp':489,629 'entorhinal-hippocampal-prefront':753 'episod':494,716 'essenti':714 'evid':155 'excit':139,705 'excitation-inhibit':138 'excitatori':112,561 'exhibit':223 'express':294 'extens':725 'fall':358 'fear':259 'featur':653 'fine':135 'fine-tun':134 'fire':225 'focal':595 'focus':8,58,331,572 'follow':481 'format':718 'frequenc':380 'function':485,723 'gamma':5,144,191,254,341,366,447,503,712,757 'gamma-guid':4 'gate':90,696 'glutam':130 'guid':6,402 'guidanc':579 'high':335,452,515 'high-dens':334,451 'high-resolut':514 'hippocamp':19,116,148,189,251,347,445,491,631,704,755 'hippocampal-prefront':18,188,444 'hz':345 'identifi':524 'ii':13,47,66,206,244,396,530,553,684 'imag':235 'includ':163,441,617 'increas':224,480 'individu':352,399,525,580 'influx':86 'inhibit':140 'intens':57,215,391 'interneuron':15,42,68,175,208,246,289,429,535,555,565,645,686,722 'involv':407,543 'ion':52 'irrevers':745 'layer':46 'lead':79,701 'level':364,477,670 'lifus':60 'like':276 'limit':603 'lobe':623 'local':111 'loop':318 'loss':170,663,708,747 'low':56,214 'low-intens':55,213 'match':465 'may':590 'measur':232,449,487 'mechan':26,31,738 'mechanosensit':71,296 'mechanotransduct':35 'mechanotransduction-medi':34 'mediat':36 'membran':81 'memori':195,260,495,675,717 'mhz':379 'mice':167,249 'millisecond':374 'minut':409 'model':158,600 'modul':121 'molecular':25,304 'monitor':326,340 'month':183 'mous':157 'mr':577 'mri':401,486,517 'mri-guid':400 'nearbi':560 'necessit':597 'neurodegener':643,726 'neurofeedback':319 'neuron':113,267,562,662,746 'neuropeptid':237 'normal':628,695 'occur':659,727 'off-target':612 'optim':427 'optogenet':239 'oscil':145 'oscillatori':277,424,671 'paramet':416,636 'patch':200 'patch-clamp':199 'path':127,699 'patholog':652,689 'patient':361,497,607 'patient-specif':360 'pattern':706 'peak':387 'penetr':593 'peptid':101 'perfor':126,698 'perform':261 'person':598 'phospho':508 'phospho-tau':507 'piezo1':72,298 'posit':41,174 'potassium':77 'potenti':537,602,733 'power':504 'precis':328,639 'preclin':154 'prefront':20,152,190,349,446,756 'preserv':527 'primari':439,540 'probabl':132 'process':632 'progress':169,658 'protocol':406 'provid':302 'rate':226 'rather':739 'ratio':512 'rational':28 'real':2,323,422,575 'real-tim':1,322,421,574 'receptor':106 'reduc':129 'region':150,350 'releas':98,119,131,230 'reli':499 'repres':647 'reproduc':273 'requir':567 'rescu':257 'resolut':516,547 'respons':211,308,425 'restor':17,250,442,720 'retain':293 'reveal':285 'revers':734 'rhythm':633 'rna':282 'robust':210 'secondari':472 'select':549,679 'sensit':51 'sequenc':283 'session':410,483 'show':209 'signific':609 'silenc':264 'singl':280 'single-cel':279 'skull':583 'somatostatin':40,100,105,120,229,476 'somatostatin-posit':39 'spatial':194,386,546 'spatial-peak':385 'specif':362,392 'sst':14,67,173,207,245,288,428,534,554,644,685,721,752 'sst-posit':172 'sstr1':107 'stage':737,751 'stereotact':403 'stimul':217,635 'strategi':310 'stratif':498 'structur':624 'studi':202 'subsequ':84 'substanti':661 'subtyp':566 'success':456 'suffici':545 'suitabl':532 'surg':95 'surviv':287 'synapt':122 'synchron':758 'synchroni':21 'system':320,371 'target':10,329,393,536,550,614,731 'task':471 'tau':509,688 'technic':541 'tempor':389,622 'temporal-averag':388 'therapeut':30,309,312,729 'thermal':433 'thermometri':578 'theta':253,711 'theta-gamma':252,710 'thick':522,584 'three':411 'threshold':353 'time':3,324,412,423,576 'tissu':434 'toxic':692 'transcrani':7,330 'transgen':156 'transmiss':123,700 'treatment':405,457,482,604 'trek':75,300 'trigger':96 'tune':136 'type':271 'ultim':142 'ultrasound':9,50,59,216,307,332,375,415,570,592 'ultrasound-sensit':49 'under':674 'unwant':618 'valu':468 'variat':581 'vesicular':97 'vitro':198 'voltag':89 'voltage-g':88 'vulner':680 'w/cm':384 'week':413 'wild':270 'wild-typ':269 'β42':511"},"change_reason":"enrich EC-II vulnerability hypotheses with evidence addenda","created_at":"2026-04-21T02:54:50.595930+00:00"}]}